PMDA drug package insert
メピバカイン塩酸塩注射液0.5%シリンジ50mg/10mL「NP」
PMDA Prescription drug · ニプロ株式会社 · package insert Mar 4, 2024
Key facts
| Brand names | メピバカイン塩酸塩注射液0.5%シリンジ50mg/10mL「NP」, メピバカイン塩酸塩注射液1%シリンジ100mg/10mL「NP」, メピバカイン塩酸塩注射液2%シリンジ200mg/10mL「NP」 |
|---|---|
| Nonproprietary names | メピバカイン塩酸塩 |
| Companies | 製造販売元／ニプロ株式会社, 発売／丸石製薬株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 局所麻酔剤 |
| Therapeutic category codes | 871214 |
| YJ codes | 1214406G1030, 1214406G2037, 1214406G3033 |
| Approval numbers | 30500AMX00001, 30500AMX00002, 30500AMX00003 |
| Package insert edition | 第1版 |
| Package insert date | Mar 4, 2024 |
| PMDA document key | 530100_1214406G1030_1 |
| PMDA company code | 530100 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: